Mostrar o rexistro simple do ítem

dc.contributor.authorTorres-Sangiao, E.
dc.contributor.authorRodriguez, B.L.
dc.contributor.authorPájaro, M.C.
dc.contributor.authorMontero, R.C.
dc.contributor.authorPazos, N.P.
dc.contributor.authorGarcía Riestra, Carlos 
dc.date.accessioned2025-08-26T09:27:52Z
dc.date.available2025-08-26T09:27:52Z
dc.date.issued2022
dc.identifier.citationTorres-Sangiao E, Rodriguez BL, Pájaro MC, Montero RC, Pazos NP, García-Riestra C. Direct Urine Resistance Detection Using VITEK 2. Antibiotics. 2022;11(5).
dc.identifier.issn2079-6382
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/632f1d594d892e5b9b217685*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20666
dc.description.abstractUrinary tract infections (UTIs) are the most common infectious diseases in both communities and hospitals. With non-anatomical or functional abnormalities, UTIs are usually self-limiting, though women suffer more reinfections throughout their lives. Certainly, antibiotic treatment leads to a more rapid resolution of symptoms, but also it selects resistant uropathogens and adversely affects the gut and vaginal microbiota. As uropathogens are increasingly becoming resistant to currently available antibiotics, it could be time to explore alternative strategies for managing UTIs. Rapid identification and antimicrobial susceptibility testing (AST) allow fast and precise treatment. The objective of this study was to shorten the time of diagnosis of UTIs by combining pathogen screening through flow cytometry, microbial identification by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS), and the VITEK 2 system for the direct analysis of urine samples. First, we selected positive urine samples by flow cytometry using UF5000, establishing the cut-off for positive at 150 bacteria/mL. After confirming the identification using MALDI-TOF MS and filtering the urine samples for Escherichia coli, we directly tested the AST N388 card using VITEK 2. We tested a total of 211 E. coli from urine samples. Cefoxitin, ertapenem, imipenem, gentamicin, nalidixic acid, ciprofloxacin, fosfomycin, and nitrofurantoin had no major important errors (MIE), and ampicillin, cefuroxime, and tobramycin showed higher MIEs. Cefepime, imipenem, and tobramycin had no major errors (ME). Fosfomycin was the antibiotic with the most MEs. The antibiotic with the most minor errors (mE) was ceftazidime. The total categorical agreement (CA) was 97.4% with a 95% CI of (96.8-97.9)95%. The direct AST from the urine samples proposed here was shorter by one day, without significant loss of sensibility regarding the standard diagnosis. Therefore, we hypothesize that this method is more realistic and better suited to human antibiotic concentrations.en
dc.description.sponsorshipThis work was supported by the Joint Programming Initiative-Antimicrobial Resistance (JPI634 AMR), the DARWIN Project [#7044-00004B], and ISCIII funding number AC16/00049. ETS was supported by a regional postdoctoral grant (Axudas de Apoio a Etapa De Formacion Posdoutoral (Modalidade A), 2016-2019), GAIN, Xunta de Galicia (ES).en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleDirect Urine Resistance Detection Using VITEK 2*
dc.typeArticleen
dc.authorsophosTorres-Sangiao, C. E.
dc.authorsophosRodriguez, B. L.
dc.authorsophosPájaro, M. C.
dc.authorsophosMontero, R. C.
dc.authorsophosPazos, N. P.
dc.authorsophosGarcía, Riestra
dc.identifier.doi10.3390/antibiotics11050663
dc.identifier.sophos632f1d594d892e5b9b217685
dc.issue.number5
dc.journal.titleAntibiotics*
dc.relation.projectIDJoint Programming Initiative-Antimicrobial Resistance [JPI634 AMR]; DARWIN Project [7044-00004B]; ISCIII [AC16/00049]; regional postdoctoral grant (Axudas de Apoio a Etapa De Formacion Posdoutoral (Modalidade A), 2016-2019), GAIN, Xunta de Galicia (ES)
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138041/pdf/antibiotics-11-00663.pdf;https://mdpi-res.com/d_attachment/antibiotics/antibiotics-11-00663/article_deploy/antibiotics-11-00663-v2.pdf?version=1652692510es
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordCHUSes
dc.subject.keywordIDISes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number11


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Atribución 4.0 Internacional
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAtribución 4.0 Internacional